Alphatec (NASDAQ:ATEC) Earns Buy Rating from HC Wainwright

Alphatec (NASDAQ:ATEC)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $20.00 price objective on the medical technology company’s stock. HC Wainwright’s price target points to a potential upside of 76.21% from the stock’s previous close.

A number of other analysts have also weighed in on ATEC. Needham & Company LLC increased their price objective on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday. Barclays raised their price target on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.44.

Alphatec Trading Up 2.1 %

ATEC stock opened at $11.35 on Tuesday. The firm’s fifty day simple moving average is $9.59 and its two-hundred day simple moving average is $8.03. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -8.87 and a beta of 1.41. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec has a twelve month low of $4.88 and a twelve month high of $17.34.

Insider Transactions at Alphatec

In related news, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the sale, the executive vice president now directly owns 502,311 shares of the company’s stock, valued at $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 22.80% of the company’s stock.

Institutional Investors Weigh In On Alphatec

Several large investors have recently modified their holdings of the business. XTX Topco Ltd purchased a new position in Alphatec during the third quarter valued at approximately $69,000. Net Worth Advisory Group bought a new stake in Alphatec during the 3rd quarter valued at $76,000. Van ECK Associates Corp increased its holdings in shares of Alphatec by 57.0% in the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after acquiring an additional 6,998 shares during the period. Tempus Wealth Planning LLC bought a new position in shares of Alphatec in the 3rd quarter worth $107,000. Finally, Atria Investments Inc lifted its stake in shares of Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after purchasing an additional 1,460 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.